Literature DB >> 10923729

Control of fever by continuous, low-dose diclofenac sodium infusion in acute cerebral damage patients.

M Cormio1, G Citerio, S Spear, R Fumagalli, A Pesenti.   

Abstract

OBJECTIVES: The aim of this study was to assess the efficacy and safety of low doses of diclofenac sodium (DCF) in attaining normothermia with minimal major side effects in patients with acute cerebral damage. The study was designed to verify the adequate, prolonged antipyretic action of DCF infusion, to quantify its haemodynamic and cerebral impact and to assess any negative effect on renal and liver function.
DESIGN: Retrospective, cohort study on prospectively collected data.
SETTING: Intensive care unit (ICU) of a university hospital. PATIENT POPULATION: Five patients with subarachnoid haemorrhage and seven severe head-trauma victims with febrile illness of various infectious origin.
INTERVENTIONS: Continuous i.v. infusion of a low dose (0.04 mg/kg/h) of DCF for 48 h. MEASUREMENTS AND
RESULTS: Systemic and cerebral haemodynamic data were collected at 4 h intervals for 8 h before diclofenac infusion and 48 h after. Renal and liver functions were monitored. Normothermia, defined as external temperature < 37.5 degrees Celsius (degrees C), was achieved in all cases. Intracranial pressure was significantly lowered and mean arterial pressure was unaffected, so cerebral perfusion pressure rose after DCF. Hepatic and renal function were not altered in the 48 h post DCF. Mean urinary output was preserved at high flow and was not influenced by DCF.
CONCLUSIONS: Continuous infusion of low-dose DCF attained normothermia without any major cerebral or systemic side effects. Renal and liver functions were unaffected. Once normothermia was achieved, intracranial and cerebral perfusion pressure improved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923729     DOI: 10.1007/s001340051203

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  7 in total

Review 1.  Fever management in SAH.

Authors:  V Scaravilli; G Tinchero; G Citerio
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

2.  Achieving normothermia in patients with febrile subarachnoid hemorrhage: feasibility and safety of a novel intravascular cooling catheter.

Authors:  Neeraj Badjatia; Joan O'Donnell; John R Baker; David Huang; Cenk Ayata; David M Greer; Bob S Carter; Christopher S Ogilvy; Colin T McDonald
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care.

Authors:  Manuela Cormio; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 4.  Continuous intravenous low-dose diclofenac sodium to control a central fever after ischemic stroke in the intensive care unit: a case report and review of the literature.

Authors:  L G Giaccari; M C Pace; M B Passavanti; P Sansone; V Esposito; C Aurilio; V Pota
Journal:  J Med Case Rep       Date:  2019-12-18

5.  Paroxysmal autonomic dysregulation with fever that was controlled by propranolol in a brain neoplasm patient.

Authors:  Su Jin Oh; Yun Kyung Hong; Eun-Kee Song
Journal:  Korean J Intern Med       Date:  2007-03       Impact factor: 2.884

6.  Parenteral diclofenac infusion significantly decreases brain-tissue oxygen tension in patients with poor-grade aneurysmal subarachnoid hemorrhage.

Authors:  Alois J Schiefecker; Bettina Pfausler; Ronny Beer; Florian Sohm; Jan Sabo; Viktoria Knauseder; Marlene Fischer; Anelia Dietmann; Werner O Hackl; Claudius Thomé; Erich Schmutzhard; Raimund Helbok
Journal:  Crit Care       Date:  2013-05-12       Impact factor: 9.097

7.  Brain Temperature Influences Intracranial Pressure and Cerebral Perfusion Pressure After Traumatic Brain Injury: A CENTER-TBI Study.

Authors:  Tatiana Birg; Fabrizio Ortolano; Eveline J A Wiegers; Peter Smielewski; Yan Savchenko; Bogdan A Ianosi; Raimund Helbok; Sandra Rossi; Marco Carbonara; Tommaso Zoerle; Nino Stocchetti
Journal:  Neurocrit Care       Date:  2021-07-30       Impact factor: 3.210

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.